| Year |
Citation |
Score |
| 2023 |
Capanu M, Giurcanu M, Begg CB, Gönen M. Subsampling based variable selection for generalized linear models. Computational Statistics & Data Analysis. 184. PMID 37090139 DOI: 10.1016/j.csda.2023.107740 |
0.599 |
|
| 2020 |
El Dika I, Capanu M, Chou JF, Harding JJ, Ly M, Hrabovsky AD, Do RKG, Shia J, Millang B, Ma J, O'Reilly EM, Abou-Alfa GK. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. Cancer Medicine. PMID 32841541 DOI: 10.1002/Cam4.3389 |
0.374 |
|
| 2020 |
Yaeger R, Paroder V, Bates DDB, Capanu M, Chou J, Tang L, Chatila W, Schultz N, Hersch J, Kelsen D. Systemic Chemotherapy for Metastatic Colitis-Associated Cancer Has a Worse Outcome Than Sporadic Colorectal Cancer: Matched Case Cohort Analysis. Clinical Colorectal Cancer. PMID 32798155 DOI: 10.1016/J.Clcc.2020.02.008 |
0.387 |
|
| 2020 |
McIntyre CA, Lawrence SA, Richards AL, Chou JF, Wong W, Capanu M, Berger MF, Donoghue MTA, Yu KH, Varghese AM, Kelsen DP, Park W, Balachandran VP, Kingham TP, D'Angelica MI, et al. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer. PMID 32573775 DOI: 10.1002/Cncr.33038 |
0.312 |
|
| 2020 |
Harding JJ, Kelley RK, Tan B, Capanu M, Kinh Do G, Shia J, Chou JF, Ferrer CS, Boussayoud C, Muenkel K, Yarmohammadi H, El Dika I, Khalil DN, Ruiz C, Lee MR, et al. Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. The Oncologist. PMID 32548867 DOI: 10.1634/Theoncologist.2020-0521 |
0.306 |
|
| 2020 |
Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, Chou JF, Segal MF, Simmons MZ, Momtaz P, Shcherba M, Ku GY, Zervoudakis A, Won ES, Kelsen DP, ... ... Capanu M, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. The Lancet. Oncology. PMID 32437664 DOI: 10.1016/S1470-2045(20)30169-8 |
0.364 |
|
| 2020 |
El Dika I, Mayer RJ, Venook AP, Capanu M, LaQuaglia MP, Kobos R, O'Neill AF, Chou JF, Ly M, Ang C, O'Reilly EM, Gordan JD, Abou-Alfa GK. A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma. The Oncologist. PMID 32400000 DOI: 10.1634/Theoncologist.2020-0367 |
0.378 |
|
| 2020 |
Capanu M, Giurcanu M, Begg CB, Gönen M. Optimized variable selection via repeated data splitting. Statistics in Medicine. PMID 32282097 DOI: 10.1002/Sim.8538 |
0.635 |
|
| 2020 |
O'Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, Brenner R, Kindler HL, Yu KH, Zervoudakis A, Vemuri S, et al. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline Mutation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902931. PMID 31976786 DOI: 10.1200/Jco.19.02931 |
0.342 |
|
| 2020 |
van Beek EJAH, Hernandez JM, Goldman DA, Davis JL, McLoughlin KC, Ripley RT, Kim TS, Tang LH, Hechtman JF, Zheng J, Capanu M, Schultz N, Hyman DM, Ladanyi M, Berger MF, et al. Correction to: Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. Annals of Surgical Oncology. PMID 31898094 DOI: 10.1245/S10434-019-08107-Y |
0.317 |
|
| 2020 |
Varghese AM, Singh I, Singh RR, Capanu M, Chou JF, Wong W, Stadler ZK, Salo-Mullen EE, Iacobuzio-Donahue CA, Kelsen DP, Park W, Yu KH, O'Reilly EM. Young-onset pancreas cancer (PC) in patients less than or equal to 50 years old at Memorial Sloan Kettering (MSK): Descriptors, genomics, and outcomes. Journal of Clinical Oncology. 38: 774-774. DOI: 10.1200/Jco.2020.38.4_Suppl.774 |
0.327 |
|
| 2020 |
Momtaz P, O'Connor CA, Chou JF, Capanu M, Yu KH, Varghese AM, Park W, Zervoudakis A, Li J, Ku GY, Reidy DL, Shcherba M, Harding JJ, Goldberg Z, Abou-Alfa GK, et al. Pancreatic ductal adenocarcinoma (PDAC), BRCA: Detailed analysis and outcomes of cohort from Memorial Sloan Kettering Cancer Center (MSK). Journal of Clinical Oncology. 38: 708-708. DOI: 10.1200/Jco.2020.38.4_Suppl.708 |
0.354 |
|
| 2020 |
O'Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, Brenner R, Kindler HL, Yu KH, Zervoudakis A, Vemuri S, et al. A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation. Journal of Clinical Oncology. 38: 639-639. DOI: 10.1200/Jco.2020.38.4_Suppl.639 |
0.334 |
|
| 2020 |
Maron SB, Chatila WK, Millang BM, Sabwa S, Chou JF, Ling L, Nagy R, Simmons M, Do RKG, Paroder V, Gerdes H, Shah PM, Ku GY, Ilson DH, Capanu M, et al. Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis. Journal of Clinical Oncology. 38: 4559-4559. DOI: 10.1200/Jco.2020.38.15_Suppl.4559 |
0.377 |
|
| 2019 |
Moy RH, Dos Santos Fernandes G, Jonsson P, Chou JF, Basunia A, Ku GY, Chalasani SB, Boyar MS, Goldberg Z, Desai AM, Gabler A, Berger MF, Tang LH, Hechtman JF, Kelsen DP, ... ... Capanu M, et al. Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. The Oncologist. PMID 31570517 DOI: 10.1634/Theoncologist.2019-0492 |
0.348 |
|
| 2019 |
Spanheimer PM, Ganly I, Chou J, Capanu M, Ghossein RA, Tuttle RM, Wong RJ, Shaha AR, Untch BR. Long-Term Oncologic Outcomes After Curative Resection of Familial Medullary Thyroid Carcinoma. Annals of Surgical Oncology. PMID 31549322 DOI: 10.1245/S10434-019-07869-9 |
0.307 |
|
| 2019 |
Himoto Y, Cybulska P, Shitano F, Sala E, Zheng J, Capanu M, Nougaret S, Nikolovski I, Vargas HA, Wang W, Mueller JJ, Chi DS, Lakhman Y. Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer? Gynecologic Oncology. PMID 31521322 DOI: 10.1016/J.Ygyno.2019.08.011 |
0.334 |
|
| 2019 |
Greally M, Chou JF, Chatila WK, Margolis M, Capanu M, Hechtman JF, Tuvy Y, Kundra R, Daian F, Ladanyi M, Kelsen DP, Ilson DH, Berger MF, Tang LH, Solit DB, et al. Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31337644 DOI: 10.1158/1078-0432.Ccr-18-3603 |
0.344 |
|
| 2019 |
Won E, Basunia A, Chatila WK, Hechtman JF, Chou JF, Ku GY, Chalasani SB, Boyar MS, Goldberg Z, Desai AM, Tuvy Y, Berger MF, Tang LH, Kelsen DP, Schattner M, ... ... Capanu M, et al. Efficacy of combined VEGFR1-3, PDGFα/β, and FGFR1-3 blockade using nintedanib for esophagogastric cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30952642 DOI: 10.1158/1078-0432.Ccr-18-3789 |
0.321 |
|
| 2019 |
Corrias G, Raeside MC, Agostini A, Huicochea-Castellanos S, Aramburu-Nunez D, Paudyal R, Shukla-Dave A, Smelianskaia O, Capanu M, Zheng J, Fung M, Kelsen DP, Mangino DA, Robson ME, Goldfrank DJ, et al. Pilot study of rapid MR pancreas screening for patients with BRCA mutation. European Radiology. PMID 30689033 DOI: 10.1007/S00330-018-5975-0 |
0.301 |
|
| 2019 |
Wong W, Lowery MA, Berger MF, Kemel Y, Taylor B, Zehir A, Srinivasan P, Bandlamudi C, Chou J, Capanu M, Varghese A, Yu KH, Iacobuzio-Donahue CA, Shia J, Klimstra DS, et al. Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes. Cancer. PMID 30620386 DOI: 10.1002/Cncr.31951 |
0.363 |
|
| 2019 |
Janjigian YY, Chou JF, Simmons M, Momtaz P, Sanchez-Vega F, Shcherba M, Ku GY, Won E, Chong CR, Gerdes H, Kelsen DP, Ilson DH, Aljallad K, Segal MF, Millang BM, ... ... Capanu M, et al. First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA). Journal of Clinical Oncology. 37: 62-62. DOI: 10.1200/Jco.2019.37.4_Suppl.62 |
0.354 |
|
| 2019 |
McIntyre CA, Lawrence SA, Wong W, Chou JF, Capanu M, Berger MF, Allen P, O'Reilly EM. KRAS and TP53 status as a predictor of survival in patients with resected pancreatic ductal adenocarcinoma. Journal of Clinical Oncology. 37: 276-276. DOI: 10.1200/Jco.2019.37.4_Suppl.276 |
0.37 |
|
| 2019 |
Greally M, Strong VE, Yoon SS, Chou JF, Capanu M, Kelsen DP, Janjigian YY, Ilson DH, Ku GY. Systemic chemo (CTX) plus surgery and intraperitoneal (IP) CTX for patients (pts) with gastric cancer (GC) and peritoneal carcinomatosis (PC). Journal of Clinical Oncology. 37: 117-117. DOI: 10.1200/Jco.2019.37.4_Suppl.117 |
0.312 |
|
| 2019 |
Raj NP, Zheng Y, Kelly V, Katz S, Chou JF, Do RKG, Capanu M, Zamarin D, Ariyan CE, Untch BR, O'Reilly EM, Gopalan A, Berger MF, Olino K, Segal NH, et al. Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma. Journal of Clinical Oncology. 37: 4112-4112. DOI: 10.1200/Jco.2019.37.15_Suppl.4112 |
0.337 |
|
| 2019 |
Greally M, Walch HS, Chou JF, Capanu M, Kelsen DP, Ilson DH, Janjigian YY, Schultz N, Ku GY. Clinical and molecular factors predicting resistance to first-line (1L) FOLFOX in patients (pts) with advanced esophagogastric cancer (EGA) and patterns of subsequent therapy. Journal of Clinical Oncology. 37: 4047-4047. DOI: 10.1200/Jco.2019.37.15_Suppl.4047 |
0.317 |
|
| 2019 |
Greally M, Strong VE, Yoon SS, Coit DG, Chou JF, Capanu M, Kelsen DP, Janjigian YY, Ilson DH, Ku GY. Total neoadjuvant chemo (ctx; TNT) for locally advanced gastric cancer (GC): The Memorial Sloan Kettering Cancer Center experience. Journal of Clinical Oncology. 37: 4046-4046. DOI: 10.1200/Jco.2019.37.15_Suppl.4046 |
0.333 |
|
| 2019 |
Kemeny NE, Hauser H, Capanu M, Kingham TP, Jarnagin WR, DeMatteo RP, Cercek A, Balachandran VP, Drebin JA, D'Angelica MI. Randomized phase II trial of adjuvant hepatic arterial infusion (HAI) + systemic FOLFIRI +/- panitumumab (Pmab) in patients with resected RAS wild type colorectal cancer hepatic metastases (CRLM). Journal of Clinical Oncology. 37: 3555-3555. DOI: 10.1200/Jco.2019.37.15_Suppl.3555 |
0.361 |
|
| 2018 |
Lowery MA, Bradley M, Chou JF, Capanu M, Gerst S, Harding JJ, Dika IE, Berger M, Zehir A, Ptashkin R, Wong P, Rasalan-Ho T, Yu KH, Cercek A, Morgono E, et al. Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30563938 DOI: 10.1158/1078-0432.Ccr-18-1927 |
0.381 |
|
| 2018 |
Yu KH, Ricigliano M, McCarthy B, Chou JF, Capanu M, Cooper B, Bartlett A, Covington C, Lowery MA, O'Reilly EM. Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma. Cancers. 10. PMID 30477242 DOI: 10.3390/Cancers10120467 |
0.345 |
|
| 2018 |
Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, ... ... Capanu M, et al. EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discovery. PMID 30463996 DOI: 10.1158/2159-8290.Cd-18-0598 |
0.35 |
|
| 2018 |
Horvat N, Raj A, Liu S, Matkowskyj KA, Knezevic A, Capanu M, Shia J, Pickhardt PJ, Gollub MJ. CT Colonography in Preoperative Staging of Colon Cancer: Evaluation of FOxTROT Inclusion Criteria for Neoadjuvant Therapy. Ajr. American Journal of Roentgenology. 1-9. PMID 30422707 DOI: 10.2214/Ajr.18.19928 |
0.364 |
|
| 2018 |
Mondaca S, Chatila WK, Bates D, Hechtman JF, Cercek A, Segal NH, Stadler ZK, Varghese AM, Kundra R, Capanu M, Shia J, Schultz N, Saltz L, Yaeger R. FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. Clinical Colorectal Cancer. PMID 30316684 DOI: 10.1016/J.Clcc.2018.09.005 |
0.357 |
|
| 2018 |
Corrias G, Krebs S, Eskreis-Winkler S, Ryan D, Zheng J, Capanu M, Saba L, Monti S, Fung M, Reeder S, Mannelli L. MRI liver fat quantification in an oncologic population: the added value of complex chemical shift-encoded MRI. Clinical Imaging. 52: 193-199. PMID 30103108 DOI: 10.1016/J.Clinimag.2018.08.002 |
0.313 |
|
| 2018 |
Mondaca S, Margolis M, Sanchez-Vega F, Jonsson P, Riches JC, Ku GY, Hechtman JF, Tuvy Y, Berger MF, Shah MA, Kelsen DP, Ilson DH, Yu K, Goldberg Z, Epstein AS, ... ... Capanu M, et al. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. PMID 30088161 DOI: 10.1007/S10120-018-0861-7 |
0.339 |
|
| 2018 |
Sahin IH, Elias H, Chou JF, Capanu M, O'Reilly EM. Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior. Bmc Cancer. 18: 769. PMID 30055578 DOI: 10.1186/S12885-018-4679-9 |
0.358 |
|
| 2018 |
van Beek EJAH, Hernandez JM, Goldman DA, Davis JL, McLaughlin K, Ripley RT, Kim TS, Tang LH, Hechtman JF, Zheng J, Capanu M, Schultz N, Hyman DM, Ladanyi M, Berger MF, et al. Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. Annals of Surgical Oncology. PMID 29725898 DOI: 10.1245/S10434-018-6502-X |
0.342 |
|
| 2018 |
Reiner AS, Sisti J, John EM, Lynch CF, Brooks JD, Mellemkjær L, Boice JD, Knight JA, Concannon P, Capanu M, Tischkowitz M, Robson M, Liang X, Woods M, Conti DV, et al. Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017773424. PMID 29620998 DOI: 10.1200/Jco.2017.77.3424 |
0.337 |
|
| 2018 |
Russo AE, Untch BR, Kris MG, Chou JF, Capanu M, Coit DG, Chaft JE, D'Angelica MI, Brennan MF, Strong VE. Adrenal Metastasectomy in the Presence and Absence of Extraadrenal Metastatic Disease. Annals of Surgery. PMID 29578911 DOI: 10.1097/Sla.0000000000002749 |
0.327 |
|
| 2018 |
Horvat N, Veeraraghavan H, Khan M, Blazic I, Zheng J, Capanu M, Sala E, Garcia-Aguilar J, Gollub MJ, Petkovska I. MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy. Radiology. 172300. PMID 29514017 DOI: 10.1148/Radiol.2018172300 |
0.325 |
|
| 2018 |
Lowery MA, Wong W, Jordan EJ, Lee JW, Kemel Y, Vijai J, Mandelker D, Zehir A, Capanu M, Salo-Mullen E, Arnold AG, Yu KH, Varghese AM, Kelsen DP, Brenner R, et al. Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal of the National Cancer Institute. PMID 29506128 DOI: 10.1093/Jnci/Djy024 |
0.363 |
|
| 2018 |
O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, et al. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer. PMID 29338080 DOI: 10.1002/Cncr.31218 |
0.344 |
|
| 2018 |
Raj NP, Kelly V, Chan JA, Dasari A, Capanu M, Tang L, Reidy DL. A phase II trial of LEE011 in combination with everolimus in the treatment of advanced well differentiated neuroendocrine tumors of foregut origin. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.4_Suppl.Tps546 |
0.352 |
|
| 2018 |
Krantz BA, Tsui D, Lowery MA, Capanu M, Yu KH, Kelsen DP, Gedvilaite E, Zhang L, Selcuklu SD, You D, Pernicka JSG, Do RKG, Iacobuzio-Donahue CA, O'Reilly EM. Plasma KRAS as a biomarker for pancreatic ductal adenocarcinoma (PDAC). Journal of Clinical Oncology. 36: 316-316. DOI: 10.1200/Jco.2018.36.4_Suppl.316 |
0.308 |
|
| 2018 |
Greally M, Molena D, Sihag S, Wu AJ, Shah PM, Fein C, Capanu M, Kelsen DP, Janjigian YY, Ilson DH, Ku GY. Phase Ib/II trial of durvalumab and chemoradiation (CRT) with carboplatin/paclitaxel for esophageal and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology. 36: 172-172. DOI: 10.1200/Jco.2018.36.4_Suppl.172 |
0.333 |
|
| 2018 |
Yaeger R, Hersch J, Bates D, Paroder V, Chou JF, Tang LH, Gollub MJ, Capanu M, Kelsen DP. Outcomes for matched patients with metastatic colitis-associated cancers versus sporadic colorectal cancer receiving chemotherapy. Journal of Clinical Oncology. 36: e15534-e15534. DOI: 10.1200/Jco.2018.36.15_Suppl.E15534 |
0.369 |
|
| 2018 |
Mondaca S, Chatila WK, Hechtman JF, Bates D, Cercek A, Segal NH, Stadler ZK, Varghese AM, Berger MF, Capanu M, Shia J, Schultz N, Saltz LB, Yaeger R. FOLFCIS regimen for treatment of cancer of the anal canal. Journal of Clinical Oncology. 36: 3567-3567. DOI: 10.1200/Jco.2018.36.15_Suppl.3567 |
0.383 |
|
| 2017 |
Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, et al. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. European Journal of Cancer (Oxford, England : 1990). 89: 19-26. PMID 29223478 DOI: 10.1016/J.Ejca.2017.11.004 |
0.371 |
|
| 2017 |
Pak LM, Kemeny NE, Capanu M, Chou JF, Boucher T, Cercek A, Balachandran VP, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D'Angelica MI. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. Journal of Surgical Oncology. PMID 29165816 DOI: 10.1002/Jso.24898 |
0.359 |
|
| 2017 |
Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, Riches JC, Tuvy Y, Kundra R, Bouvier N, Vakiani E, Gao J, Heins ZJ, Gross BE, Kelsen DP, ... ... Capanu M, et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discovery. PMID 29122777 DOI: 10.1158/2159-8290.Cd-17-0787 |
0.38 |
|
| 2017 |
Varghese AM, Arora A, Capanu M, Camacho N, Won HH, Zehir A, Gao J, Chakravarty D, Schultz N, Klimstra DS, Ladanyi M, Hyman DM, Solit DB, Berger MF, Saltz LB. Clinical and molecular characterization of patients with cancers of unknown primary in the modern era. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29045506 DOI: 10.1093/Annonc/Mdx545 |
0.386 |
|
| 2017 |
Cercek A, Gendel V, Jabbour S, Moore D, Chen C, Nosher J, Capanu M, Chou JF, Boucher T, Kemeny N, Carpizo DR. A Comparison of Yttrium-90 Microsphere Radioembolization to Hepatic Arterial Infusional Chemotherapy for Patients with Chemo-refractory Hepatic Colorectal Metastases. Current Treatment Options in Oncology. 18: 42. PMID 28608276 DOI: 10.1007/S11864-017-0481-1 |
0.351 |
|
| 2017 |
Cercek A, Braghiroli MI, Chou JF, Hechtman JF, Kemeny NE, Saltz L, Capanu M, Yaeger R. Clinical features and outcomes of patients with colorectal cancers harboring NRAS mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28446505 DOI: 10.1158/1078-0432.Ccr-17-0400 |
0.32 |
|
| 2017 |
Halpenny DF, McEvoy S, Li A, Hayan S, Capanu M, Zheng J, Riely G, Ginsberg MS. Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics. Lung Cancer (Amsterdam, Netherlands). 106: 33-36. PMID 28285691 DOI: 10.1016/J.Lungcan.2017.01.010 |
0.303 |
|
| 2017 |
Boucher TM, Kemeny NE, Chou JF, Capanu M, Lowery MA, Cercek A. Analysis of prior malignancies in patients with cholangiocarcinoma. Journal of Clinical Oncology. 35: 305-305. DOI: 10.1200/Jco.2017.35.4_Suppl.305 |
0.346 |
|
| 2017 |
Lowery MA, Harding JJ, Yu KH, Kelsen DP, Bomalaski JS, Glassman DC, Covington CM, Brenner R, Hollywood E, Barba A, Johnston A, Liu KC, Capanu M, Abou-Alfa GK, O'Reilly EM. Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC). Journal of Clinical Oncology. 35: 295-295. DOI: 10.1200/Jco.2017.35.4_Suppl.295 |
0.334 |
|
| 2017 |
Lowery MA, O'Reilly EM, Harding JJ, Yu KH, Cercek A, Hollywood E, Salehi E, Margona E, Bradley M, Witter T, Gerst SR, Capanu M, Saltz L, Abou-Alfa GK. A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC). Journal of Clinical Oncology. 35: 290-290. DOI: 10.1200/Jco.2017.35.4_Suppl.290 |
0.338 |
|
| 2017 |
Askan G, Sahin IH, Capanu M, Turkekul M, Yu KH, Lowery MA, Basturk O, Iacobuzio-Donahue C, O'Reilly EM. Do pancreas cancer stem cells play crucial role in survival outcome Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E15721 |
0.343 |
|
| 2017 |
Kelsen DP, Miller VA, Tang LH, Capanu M, Balasubramanian S, Ross JS, Stephens PJ, Yaeger R. Clinical and genomic alterations features of patients with advanced colitis associated cancers (CAC). Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E15010 |
0.318 |
|
| 2016 |
Connell LC, Boucher TM, Chou JF, Capanu M, Maldonado S, Kemeny NE. Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases. Journal of Surgical Oncology. PMID 28008623 DOI: 10.1200/Jco.2016.34.4_Suppl.762 |
0.372 |
|
| 2016 |
Cercek A, Boucher TM, Gluskin JS, Aguiló A, Chou JF, Connell LC, Capanu M, Reidy-Lagunes D, D'Angelica M, Kemeny NE. Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies. Journal of Surgical Oncology. PMID 27566258 DOI: 10.1002/Jso.24399 |
0.379 |
|
| 2016 |
Won E, Shah MA, Schöder H, Strong VE, Coit DG, Brennan MF, Kelsen DP, Janjigian YY, Tang LH, Capanu M, Rizk NP, Allen PJ, Bains MS, Ilson DH. Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. Journal of Gastrointestinal Oncology. 7: 506-14. PMID 27563439 DOI: 10.21037/Jgo.2016.06.01 |
0.314 |
|
| 2016 |
Ku GY, Kriplani A, Janjigian YY, Kelsen DP, Rusch VW, Bains M, Chou J, Capanu M, Wu AJ, Goodman KA, Ilson DH. Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. Cancer. PMID 27152857 DOI: 10.1002/Cncr.30028 |
0.318 |
|
| 2016 |
Kemeny NE, Chou JF, Boucher TM, Capanu M, DeMatteo RP, Jarnagin WR, Allen PJ, Fong YC, Cercek A, D'Angelica MI. Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. Journal of Surgical Oncology. PMID 26830685 DOI: 10.1002/Jso.24189 |
0.384 |
|
| 2016 |
Davis JL, Selby LV, Chou JF, Schattner M, Ilson DH, Capanu M, Brennan MF, Coit DG, Strong VE. Patterns and Predictors of Weight Loss After Gastrectomy for Cancer. Annals of Surgical Oncology. PMID 26732274 DOI: 10.1245/S10434-015-5065-3 |
0.319 |
|
| 2016 |
Lowery MA, Goff LW, Jordan E, Wang R, Bocobo AG, Chou JF, O'Reilly EM, Harding JJ, Kemeny NE, Capanu M, Griffin A, McGuire JP, Venook AP, Abou-Alfa GK, Kelley RK. Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis. Journal of Clinical Oncology. 34: 437-437. DOI: 10.1200/Jco.2016.34.4_Suppl.437 |
0.353 |
|
| 2016 |
Hicks AM, O'Reilly EM, Capanu M, Lowery MA, Yu KH. Presentation, clinical behavior, outcomes and therapies for patients with advanced pancreas adenocarcinoma (PAC) who present with or develop ascites. Journal of Clinical Oncology. 34: 209-209. DOI: 10.1200/Jco.2016.34.4_Suppl.209 |
0.357 |
|
| 2016 |
Lowe MC, Chou JF, Capanu M, Coit DG. Evaluation of the effects of neoadjuvant therapy on stage specific outcome estimates in patients with completely resected gastric cancer. Journal of Clinical Oncology. 34: 139-139. DOI: 10.1200/Jco.2016.34.4_Suppl.139 |
0.389 |
|
| 2016 |
Braghiroli MI, Chou JF, Hechtman JF, Capanu M, Cercek A, Yaeger R. Clinical characteristics and outcomes of patients with metastatic colorectal cancer (CRC) harboring NRAS mutations Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw370.119 |
0.354 |
|
| 2016 |
Ma LW, Kemeny NE, Capanu M, Chou J, Cercek A, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D'Angelica MI. Prospective Phase II Trial of Combination Hepatic Artery and Systemic Chemotherapy for Unresectable Colorectal Liver Metastases: Long-Term Results and Curative Potential Journal of the American College of Surgeons. 223. DOI: 10.1016/J.Jamcollsurg.2016.06.151 |
0.32 |
|
| 2015 |
Shah MA, Janjigian YY, Stoller R, Shibata S, Kemeny M, Krishnamurthi S, Su YB, Ocean A, Capanu M, Mehrotra B, Ritch P, Henderson C, Kelsen DP. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26438119 DOI: 10.1200/Jco.2015.60.7465 |
0.326 |
|
| 2015 |
Janjigian YY, Vakiani E, Ku GY, Herrera JM, Tang LH, Bouvier N, Viale A, Socci ND, Capanu M, Berger M, Ilson DH. Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. Plos One. 10: e0134731. PMID 26275293 DOI: 10.1371/Journal.Pone.0134731 |
0.436 |
|
| 2015 |
Li D, Capanu M, Yu KH, Lowery MA, Kelsen DP, O'Reilly EM. Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. Clinical Colorectal Cancer. PMID 26072442 DOI: 10.1016/J.Clcc.2015.05.005 |
0.386 |
|
| 2015 |
Wang SC, Chou JF, Strong VE, Brennan MF, Capanu M, Coit DG. Pretreatment Neutrophil to Lymphocyte Ratio Independently Predicts Disease-specific Survival in Resectable Gastroesophageal Junction and Gastric Adenocarcinoma. Annals of Surgery. PMID 25915915 DOI: 10.1097/Sla.0000000000001189 |
0.308 |
|
| 2015 |
Yaeger R, Cercek A, O'Reilly EM, Reidy DL, Kemeny N, Wolinsky T, Capanu M, Gollub MJ, Rosen N, Berger MF, Lacouture ME, Vakiani E, Saltz LB. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1313-20. PMID 25589621 DOI: 10.1158/1078-0432.Ccr-14-2779 |
0.407 |
|
| 2015 |
Yaeger R, Cowell E, Chou JF, Gewirtz AN, Borsu L, Vakiani E, Solit DB, Rosen N, Capanu M, Ladanyi M, Kemeny N. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer. 121: 1195-203. PMID 25491172 DOI: 10.1002/Cncr.29196 |
0.311 |
|
| 2015 |
Janjigian YY, Riches JC, Ku GY, Imtiaz T, Capanu M, Chou JF, Kelsen DP, Ilson DH, Berger MF, Vakiani E. Loss of human epidermal growth factor receptor 2 (HER2) expression in HER2-overexpressing esophagogastric (EG) tumors treated with trastuzumab. Journal of Clinical Oncology. 33: 63-63. DOI: 10.1200/Jco.2015.33.3_Suppl.63 |
0.39 |
|
| 2015 |
Lowery MA, Kelsen DP, Smith SC, Moore M, Kindler HL, Golan T, Segal A, Hollywood E, Maynard H, Capanu M, Moynahan ME, Fusco A, Stadler ZK, Do KG, Chen AP, et al. Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC). Journal of Clinical Oncology. 33: 358-358. DOI: 10.1200/Jco.2015.33.3_Suppl.358 |
0.378 |
|
| 2015 |
Raj NP, Valentino E, Tang LH, Capanu M, Basturk O, Klimstra D, Reidy DL. Treatment response and outcomes of grade 3 (G3) pancreatic neuroendocrine carcinomas (HGNEC) based on pathologic differentiation. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E15185 |
0.37 |
|
| 2015 |
Abou-Alfa GK, Mayer RJ, Cosgrove D, Capanu M, Choti MA, Atreya CE, Ang C, Kelley RK, Do RKG, Gordan JD, Zhu AX, Ly M, Nolan P, Lubin L, Harding JJ, et al. Randomized phase II study of everolimus (E), leuprolide + letrozole (LL), and E + LL (ELL) in patients (pts) with unresectable fibrolamellar carcinoma (FLC). Journal of Clinical Oncology. 33: e15149-e15149. DOI: 10.1200/Jco.2015.33.15_Suppl.E15149 |
0.34 |
|
| 2015 |
Abou-Alfa GK, Capanu M, Do RKG, Hollywood E, Ly M, Chou JF, Lee JK, Connell LC, Wan PJ, Bradley M, Harding JJ, Saltz L. First stage results of a phase II trial of sorafenib plus doxorubicin (SD) in patients (pts) with advanced hepatocellular carcinoma (HCC) who progressed (POD) on sorafenib (S). Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E15147 |
0.345 |
|
| 2015 |
Lowery MA, O'Reilly EM, Harding JJ, Salehi E, Hollywood E, Bradley M, Sophos NA, Ly M, Capanu M, Gerst SR, Saltz L, Abou-Alfa GK. A phase I trial of binimetinib in combination with gemcitabine (G) and cisplatin (C) patients (pts) with untreated advanced biliary cancer (ABC). Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E15125 |
0.326 |
|
| 2015 |
Janjigian YY, Ku GY, Chou JF, Capanu M, Siebel M, Chalasani SB, Boyar MS, Goldberg Z, Desai AM, Kelsen DP, Imtiaz T, Ilson DH. Phase II study of FOLFOX plus regorafenib (REGO) in patients with unresectable or metastatic esophagogastric (EG) cancer. Journal of Clinical Oncology. 33: 4053-4053. DOI: 10.1200/Jco.2015.33.15_Suppl.4053 |
0.388 |
|
| 2015 |
Kemeny NE, Chou JF, Boucher TM, Capanu M, DeMatteo RP, Jarnagin WR, Kingham TP, Allen PJ, Fong Y, Cercek A, D'Angelica MI. Improvement in long-term survival in patients with metastatic colorectal cancer (CRC) after liver resection with modern chemotherapy and hepatic arterial infusion (HAI). Journal of Clinical Oncology. 33: 3563-3563. DOI: 10.1200/Jco.2015.33.15_Suppl.3563 |
0.38 |
|
| 2014 |
Cercek A, Shia J, Gollub M, Chou JF, Capanu M, Raasch P, Reidy-Lagunes D, Proia DA, Vakiani E, Solit DB, Saltz LB. Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer. Clinical Colorectal Cancer. 13: 207-12. PMID 25444464 DOI: 10.1016/J.Clcc.2014.09.001 |
0.421 |
|
| 2014 |
Kemeny NE, Chou JF, Capanu M, Gewirtz AN, Cercek A, Kingham TP, Jarnagin WR, Fong YC, DeMatteo RP, Allen PJ, Shia J, Ang C, Vakiani E, D'Angelica MI. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer. 120: 3965-71. PMID 25155157 DOI: 10.1002/Cncr.28954 |
0.377 |
|
| 2014 |
OʼReilly EM, Perelshteyn A, Jarnagin WR, Schattner M, Gerdes H, Capanu M, Tang LH, LaValle J, Winston C, DeMatteo RP, DʼAngelica M, Kurtz RC, Abou-Alfa GK, Klimstra DS, Lowery MA, et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Annals of Surgery. 260: 142-8. PMID 24901360 DOI: 10.1097/Sla.0000000000000251 |
0.371 |
|
| 2014 |
Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, Ladanyi M, Rosen N, Weiser MR, Capanu M, Solit DB, D'Angelica MI, Vakiani E, Saltz LB. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer Cancer. 120: 2316-2324. PMID 24737664 DOI: 10.1002/Cncr.28729 |
0.37 |
|
| 2014 |
Sofocleous CT, Garcia AR, Pandit-Taskar N, Do KG, Brody LA, Petre EN, Capanu M, Longing AP, Chou JF, Carrasquillo JA, Kemeny NE. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clinical Colorectal Cancer. 13: 27-36. PMID 24370352 DOI: 10.1016/J.Clcc.2013.11.010 |
0.408 |
|
| 2014 |
Abou-Alfa GK, Capanu M, O'Reilly EM, Ma J, Chou JF, Gansukh B, Shia J, Kalin M, Katz S, Abad L, Reidy-Lagunes DL, Kelsen DP, Chen HX, Saltz LB. A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. Journal of Hepatology. 60: 319-24. PMID 24045151 DOI: 10.1016/J.Jhep.2013.09.008 |
0.34 |
|
| 2014 |
Janjigian YY, Ku GY, Campbell JC, Shah MA, Capanu M, Kelsen DP, Ilson DH. Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer. American Journal of Clinical Oncology. 37: 126-30. PMID 23211227 DOI: 10.1097/Coc.0B013E318271B14F |
0.429 |
|
| 2014 |
Ku GY, Janjigian YY, Kriplani A, Ong L, Rusch VW, Bains MS, Rizk NP, Sarkaria IS, Capanu M, Goodman KA, Ilson DH. FDG-PET scan after induction chemotherapy for esophageal squamous cell cancer (ESCC) to predict for outcomes after chemoradiation (chemoRT) and to guide salvage chemotherapy during RT. Journal of Clinical Oncology. 32: 94-94. DOI: 10.1200/Jco.2014.32.3_Suppl.94 |
0.339 |
|
| 2014 |
Cercek A, Aguilo A, Gluskin J, Chou JF, Reidy DL, Saltz L, Siegel C, Capanu M, Jarnagin WR, DeMatteo RP, Allen PJ, Kingham PT, Fong Y, D'Angelica MI, Kemeny NE. Response rates to hepatic arterial infusion (HAI) pump therapy in patients with metastatic colorectal cancer liver metastases (mCRC LM) after progression on all standard chemotherapies. Journal of Clinical Oncology. 32: 3623-3623. DOI: 10.1200/Jco.2014.32.3_Suppl.597 |
0.376 |
|
| 2014 |
Ang C, Gewirtz AN, Chou JF, Capanu M, Vakiani E, Kemeny NE. Impact of KRAS on outcomes of patients with unresectable colorectal liver metastases (CRLM). Journal of Clinical Oncology. 32: 510-510. DOI: 10.1200/Jco.2014.32.3_Suppl.510 |
0.384 |
|
| 2014 |
Kim S, Brown KT, Fong Y, Solomon SB, Chou JF, Capanu M, Harding JJ, O'Reilly EM, Saltz L, Abou-Alfa GK. Embolization versus embolization and systemic therapy in patients with hepatocellular carcinoma and metastatic disease: A retrospective analysis. Journal of Clinical Oncology. 32: 363-363. DOI: 10.1200/Jco.2014.32.3_Suppl.363 |
0.364 |
|
| 2014 |
Lee JK, Harding JJ, Chou JF, Capanu M, Saltz L, Abou-Alfa GK. Prognostic role of C-reactive protein levels in patients with hepatocellular carcinoma undergoing sorafenib therapy. Journal of Clinical Oncology. 32: 340-340. DOI: 10.1200/Jco.2014.32.3_Suppl.340 |
0.341 |
|
| 2014 |
Won E, Ilson DH, Chou JF, Capanu M. Activity of gemcitabine/5-FU combination in refractory esophagogastric (EG) cancer. Journal of Clinical Oncology. 32: 147-147. DOI: 10.1200/Jco.2014.32.3_Suppl.147 |
0.364 |
|
| 2014 |
Epstein AS, Crosbie C, Martin S, Egan B, Goring T, Koo D, Kumar C, Salvit C, Capanu M, Saltz L. Medical oncology patient readmissions: Are they preventable? Journal of Clinical Oncology. 32: 6589-6589. DOI: 10.1200/Jco.2014.32.15_Suppl.6589 |
0.329 |
|
| 2014 |
Li D, Capanu M, Yu KH, Lowery MA, Kelsen DP, O'Reilly EM. Treatment, outcomes, and clinical trial participation in very elderly patients (pts) with metastatic pancreas cancer (mPC). Journal of Clinical Oncology. 32: 4119-4119. DOI: 10.1200/Jco.2014.32.15_Suppl.4119 |
0.366 |
|
| 2014 |
Wang SC, Chou JF, Strong VE, Brennan MF, Capanu M, Coit DG. Pretreatment neutrophil to lymphocyte ratio as an independent predictor of disease-specific survival in resectable GE junction and gastric adenocarcinoma. Journal of Clinical Oncology. 32: 4056-4056. DOI: 10.1200/Jco.2014.32.15_Suppl.4056 |
0.36 |
|
| 2013 |
Cercek A, Siegel CL, Capanu M, Reidy-Lagunes D, Saltz LB. Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant folfox for colorectal cancer Clinical Colorectal Cancer. 12: 163-167. PMID 23871161 DOI: 10.1016/J.Clcc.2013.04.007 |
0.389 |
|
| 2013 |
Bernstein JL, Thomas DC, Shore RE, Robson M, Boice JD, Stovall M, Andersson M, Bernstein L, Malone KE, Reiner AS, Lynch CF, Capanu M, Smith SA, Tellhed L, Teraoka SN, et al. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report. European Journal of Cancer (Oxford, England : 1990). 49: 2979-85. PMID 23706288 DOI: 10.1016/J.Ejca.2013.04.028 |
0.31 |
|
| 2013 |
Reiner AS, John EM, Brooks JD, Lynch CF, Bernstein L, Mellemkjær L, Malone KE, Knight JA, Capanu M, Teraoka SN, Concannon P, Liang X, Figueiredo JC, Smith SA, Stovall M, et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 433-9. PMID 23269995 DOI: 10.1200/Jco.2012.43.2013 |
0.323 |
|
| 2013 |
Won E, Ilson D, Kelsen DP, Strong VE, Schöder H, Janjigian YY, Shah MA, Coit DG, Brennan MF, Capanu M. Phase II study of preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in patients with locally advanced gastric and GEJ adenocarcinoma. Journal of Clinical Oncology. 31: 94-94. DOI: 10.1200/Jco.2013.31.4_Suppl.94 |
0.32 |
|
| 2013 |
Kemeny NE, Chou JF, Capanu M, Gewirtz AN, Cercek A, Kingham TP, Jarnagin WR, Fong Y, DeMatteo RP, Allen PJ, Shia J, Ang C, Vakiani E, D'Angelica MI. Influence of KRAS mutation on recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Journal of Clinical Oncology. 31: 398-398. DOI: 10.1200/Jco.2013.31.4_Suppl.398 |
0.407 |
|
| 2013 |
O'Reilly EM, Lowery MA, Yu KH, Capanu M, Stadler ZK, Epstein AS, Golan T, Segal A, Segal M, Salo-Mullen EE, Tang LH, Hollywood E, Moynahan ME, Do KG, Moore MJ, et al. Randomized phase II study of gemcitabine (G), cisplatin (C) with or without veliparib (V) (arms A, B) and a phase II single-arm study of single-agent veliparib (arm C) in patients with BRCA or PALB2-mutated pancreas adenocarcinoma (PC). Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps4144 |
0.325 |
|
| 2013 |
Reidy DL, Pietanza MC, Segal M, Capanu M, Saltz L. A phase II clinical and translational study of MK-2206 in patients with metastatic neuroendocrine tumors (NETs). Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E15133 |
0.348 |
|
| 2013 |
Janjigian YY, Capanu M, Gromisch CM, Kelsen DP, Ku GY, Brown KT, Schattner M, Ilson DH, Solit DB, Berger MF, Vakiani E. A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab-refractory esophagogastric (EG) cancer. Journal of Clinical Oncology. 31: 52-52. DOI: 10.1200/Jco.2013.31.15_Suppl.E15017 |
0.374 |
|
| 2013 |
Ku GY, Kelsen DP, Strong VE, Schöder H, Janjigian YY, Shah MA, Coit DG, Brennan MF, Capanu M, Ilson DH. Preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in locally advanced gastroesophageal junction and gastric adenocarcinoma. Journal of Clinical Oncology. 31: 4101-4101. DOI: 10.1200/Jco.2013.31.15_Suppl.4101 |
0.306 |
|
| 2013 |
Kemeny NE, Chou JF, Capanu M, Gewirtz AN, Cercek A, Kingham TP, Jarnagin WR, Fong Y, DeMatteo RP, Allen PJ, Shia J, Ang C, Vakiani E, D'Angelica MI. Association of KRAS mutation with worse recurrence-free survival and site of metastatic progression after resection of hepatic colorectal metastases. Journal of Clinical Oncology. 31: 3609-3609. DOI: 10.1200/Jco.2013.31.15_Suppl.3609 |
0.391 |
|
| 2012 |
Sofocleous CT, Kemeny NE, Pandit-Taskar N, Do KG, Brody LA, Garcia AR, Capanu M, Chou JF, Petre EN, Carrasquillo JA. Phase I trial of yttrium 90 resin microspheres in the treatment of colon cancer liver metastases progressing despite hepatic arterial as well as systemic chemotherapy: Preliminary results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 625. PMID 27983368 DOI: 10.1200/Jco.2012.30.4_Suppl.625 |
0.378 |
|
| 2012 |
Ilson D, Goodman KA, Janjigian YY, Shah MA, Kelsen DP, Rizk NP, Rusch VW, Wu AJ, Campbell J, Capanu M, Bains MS. Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 67. PMID 27982882 DOI: 10.1200/Jco.2012.30.15_Suppl.4061 |
0.361 |
|
| 2012 |
Abou-Alfa GK, Ma J, O'Reilly EM, Gansukh B, Chou JF, Capanu M, Saltz L. Retrospective review of doxorubicin plus sorafenib as second-line therapy in hepatocellular carcinoma (HCC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 298. PMID 27982822 DOI: 10.1200/Jco.2012.30.4_Suppl.298 |
0.317 |
|
| 2012 |
Reidy-Lagunes DL, Vakiani E, Segal MF, Hollywood EM, Tang LH, Solit DB, Pietanza MC, Capanu M, Saltz LB. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer. 118: 4795-800. PMID 22437754 DOI: 10.1002/Cncr.27459 |
0.347 |
|
| 2012 |
Smyth EC, Capanu M, Janjigian YY, Kelsen DK, Coit D, Strong VE, Shah MA. Tobacco use is associated with increased recurrence and death from gastric cancer. Annals of Surgical Oncology. 19: 2088-94. PMID 22395977 DOI: 10.1245/S10434-012-2230-9 |
0.334 |
|
| 2012 |
Tischkowitz M, Capanu M, Sabbaghian N, Li L, Liang X, Vallée MP, Tavtigian SV, Concannon P, Foulkes WD, Bernstein L, Bernstein JL, Begg CB. Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Human Mutation. 33: 674-80. PMID 22241545 DOI: 10.1002/Humu.22022 |
0.331 |
|
| 2012 |
Ilson DH, Minsky BD, Ku GY, Rusch V, Rizk N, Shah M, Kelsen DP, Capanu M, Tang L, Campbell J, Bains M. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer. 118: 2820-7. PMID 21990000 DOI: 10.1002/Cncr.26591 |
0.425 |
|
| 2012 |
Epstein AS, Soff GA, Capanu M, Crosbie C, Shah MA, Kelsen DP, Denton B, Gardos S, O'Reilly EM. Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer. 118: 3053-61. PMID 21989534 DOI: 10.1002/Cncr.26600 |
0.362 |
|
| 2012 |
Kemeny NE, Fong Y, Paty P, Chou JF, Capanu M, Gewirtz AN, Jarnagin WR, DeMatteo RP, Allen PJ, Kingham TP, Ang C, Cercek A, D'Angelica MI. Is conversion to resection possible with hepatic arterial infusion (HAI) and systemic (SYS) even in previously treated patients (pts) with unresectable colorectal liver metastases (UnCLM) Journal of Clinical Oncology. 30: 3577-3577. DOI: 10.1200/Jco.2012.30.15_Suppl.3577 |
0.347 |
|
| 2012 |
Sofocleous C, Pandit-Taskar N, Do K, Brody L, Petre E, Siegelbaum R, Garcia A, Capanu M, Chou J, Alago W, Carrasquillo J, Kemeny N. Abstract No. 168: Yttrium 90 resin microspheres as a salvage treatment for colon cancer liver metastases progressing after at least two prior lines of systemic chemotherapy: preliminary results Journal of Vascular and Interventional Radiology. 23: S70. DOI: 10.1016/J.Jvir.2011.12.213 |
0.361 |
|
| 2012 |
Sofocleous C, Pandit-Taskar N, Do K, Brody L, Siegelbaum R, Garcia A, Capanu M, Chou J, Petre E, Carrasquillo J, Kemeny N. Abstract No. 166: Phase I trial of yttrium 90 resin microspheres in the treatment of colon cancer liver metastases progressing despite hepatic arterial as well as systemic chemotherapy: preliminary results Journal of Vascular and Interventional Radiology. 23: S69-S70. DOI: 10.1016/J.Jvir.2011.12.211 |
0.353 |
|
| 2011 |
Maddox GJ, Chou JF, Capanu M, Patel D, D'Angelica MI, Kemeny NE. Is PET scan conversion from positive to negative a prognostic indicator for patients receiving therapy for unresectable liver metastases from colorectal carcinoma (CRC)? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e14053. PMID 28022666 DOI: 10.1200/Jco.2011.29.15_Suppl.E14053 |
0.355 |
|
| 2011 |
Lowery MA, Gallagher DJ, Capanu M, Chou JF, Kemeny NE. Clinical outcomes in patients age 40 or younger at diagnosis of synchronous metastatic colorectal cancer: A 20-year experience at Memorial Sloan-Kettering Cancer Center. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e14050. PMID 28022665 DOI: 10.1200/Jco.2011.29.15_Suppl.E14050 |
0.349 |
|
| 2011 |
O'Reilly EM, Jarnagin WR, Brennan MF, Winston C, Tang LH, Capanu M, Schattner M, Chen LY, DeMatteo RP, DiMaio CJ, D'Angelica MI, Kurtz RC, Klimstra DS, Lowery MA, Coit DG, et al. Phase II single-arm, single-institution trial of neoadjuvant gemcitabine and oxaliplatin treatment (NT) in patients (pts) with resectable pancreas adenocarcinoma (PC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4065. PMID 28020487 DOI: 10.1200/Jco.2011.29.15_Suppl.4065 |
0.343 |
|
| 2011 |
Teraoka SN, Bernstein JL, Reiner AS, Haile RW, Bernstein L, Lynch CF, Malone KE, Stovall M, Capanu M, Liang X, Smith SA, Mychaleckyj J, Hou X, Mellemkjaer L, Boice JD, et al. Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study. Breast Cancer Research : Bcr. 13: R114. PMID 22087758 DOI: 10.1186/Bcr3057 |
0.314 |
|
| 2011 |
Capanu M, Concannon P, Haile RW, Bernstein L, Malone KE, Lynch CF, Liang X, Teraoka SN, Diep AT, Thomas DC, Bernstein JL, Begg CB. Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling. Genetic Epidemiology. 35: 389-97. PMID 21520273 DOI: 10.1002/Gepi.20587 |
0.314 |
|
| 2011 |
Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, Capanu M, Miron B, Klimstra D. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer. 117: 1409-14. PMID 21425140 DOI: 10.1002/Cncr.25602 |
0.391 |
|
| 2011 |
Kemeny NE, Jarnagin WR, Capanu M, Fong Y, Gewirtz AN, Dematteo RP, D'Angelica MI. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 884-9. PMID 21189384 DOI: 10.1200/Jco.2010.32.5977 |
0.363 |
|
| 2011 |
Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 868-74. PMID 21189380 DOI: 10.1200/Jco.2010.32.0770 |
0.344 |
|
| 2011 |
Shah MA, Power DG, Kindler HL, Holen KD, Kemeny MM, Ilson DH, Tang L, Capanu M, Wright JJ, Kelsen DP. A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Investigational New Drugs. 29: 1475-81. PMID 20574790 DOI: 10.1007/S10637-010-9474-7 |
0.338 |
|
| 2011 |
Ku GY, Janjigian YY, Shah MA, Herrera J, Tang LH, Fuqua L, Capanu M, Ilson D. Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and prolonged stable disease observed in adenocarcinoma. Journal of Clinical Oncology. 29: 4100-4100. DOI: 10.1200/Jco.2013.31.4_Suppl.91 |
0.395 |
|
| 2011 |
Brooks JD, Thomas DC, Haile RW, Smith SA, Capanu M, Bernstein JL, Shore RE, Boice JD, Stovall M, Reiner AS, Bernstein L, John EM, Lynch CF, Mellemkjaer L, Knight JA. Abstract B54: Reproductive status at first diagnosis influences risk of radiation-induced second primary contralateral breast cancer in The WECARE Study Cancer Prevention Research. 4. DOI: 10.1158/1940-6207.Prev-11-B54 |
0.31 |
|
| 2010 |
Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. Jama. 304: 2154-60. PMID 21081728 DOI: 10.1001/Jama.2010.1672 |
0.348 |
|
| 2010 |
Shah MA, Capanu M, Soff G, Asmis T, Kelsen DP. Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies. Journal of Thrombosis and Haemostasis. 8: 1702-1709. PMID 20553384 DOI: 10.1111/J.1538-7836.2010.03948.X |
0.392 |
|
| 2010 |
Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL, Abou-Alfa GK. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2889-95. PMID 20458042 DOI: 10.1200/Jco.2009.25.9895 |
0.348 |
|
| 2010 |
Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, Xue S, Teraoka S, Bernstein L, Capanu M, Reiner AS, Riedel ER, Thomas DC, Mellemkjaer L, Lynch CF, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2404-10. PMID 20368571 DOI: 10.1200/Jco.2009.24.2495 |
0.319 |
|
| 2010 |
Reding KW, Bernstein JL, Langholz BM, Bernstein L, Haile RW, Begg CB, Lynch CF, Concannon P, Borg A, Teraoka SN, Törngren T, Diep A, Xue S, Bertelsen L, Liang X, ... ... Capanu M, et al. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Research and Treatment. 123: 491-8. PMID 20135344 DOI: 10.1007/S10549-010-0769-3 |
0.343 |
|
| 2010 |
Poynter JN, Langholz B, Largent J, Mellemkjaer L, Bernstein L, Malone KE, Lynch CF, Borg A, Concannon P, Teraoka SN, Xue S, Diep AT, Törngren T, Begg CB, Capanu M, et al. Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study. Cancer Causes & Control : Ccc. 21: 839-46. PMID 20130978 DOI: 10.1007/S10552-010-9510-0 |
0.307 |
|
| 2010 |
Borg A, Haile RW, Malone KE, Capanu M, Diep A, Törngren T, Teraoka S, Begg CB, Thomas DC, Concannon P, Mellemkjaer L, Bernstein L, Tellhed L, Xue S, Olson ER, et al. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Human Mutation. 31: E1200-40. PMID 20104584 DOI: 10.1002/Humu.21202 |
0.309 |
|
| 2010 |
Figueiredo JC, Haile RW, Bernstein L, Malone KE, Largent J, Langholz B, Lynch CF, Bertelsen L, Capanu M, Concannon P, Borg A, Børresen-Dale AL, Diep A, Teraoka S, Torngren T, et al. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study. Breast Cancer Research and Treatment. 120: 175-83. PMID 19597986 DOI: 10.1007/S10549-009-0455-5 |
0.32 |
|
| 2010 |
Smyth EC, Schöder H, Coit DG, Strong VE, Brennan MF, Janjigian YY, Capanu M, Tang LH, Kelsen DP, Shah MA. Perioperative chemotherapy plus bevacizumab with early salvage therapy based on PET response in patients with locally advanced resectable gastric/GEJ cancer. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps200 |
0.37 |
|
| 2010 |
Smyth EC, Strong VE, Capanu M, Janjigian YY, Coit DG, Kelsen DP, Shah MA. Association between smoking history and disease-free and overall survival in resected gastric cancer. Journal of Clinical Oncology. 28: 4095-4095. DOI: 10.1200/Jco.2010.28.15_Suppl.4095 |
0.334 |
|
| 2010 |
Reiner AS, Begg CB, Bernstein L, Haile RW, Knight JA, Lynch CF, John EM, Capanu M, Pike MC, Bernstein JL. Abstract B127: Family history of breast cancer and risk of contralateral breast cancer Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-09-B127 |
0.317 |
|
| 2009 |
Feilchenfeldt JW, Capanu M, Farooki A, Sully D, Miron B, Power DG, Jhawer M, Ilson DH, Kelsen DP, Shah MA. Diabetes mellitus (DM), serum glucose, and outcome in gastroesophageal (GE) cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e15661. PMID 27962769 DOI: 10.1200/Jco.2009.27.15_Suppl.E15661 |
0.35 |
|
| 2009 |
Kelsen D, Jhawer M, Ilson D, Tse A, Randazzo J, Robinson E, Capanu M, Shah MA. Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4512. PMID 27962705 DOI: 10.1200/Jco.2009.27.15_Suppl.4512 |
0.421 |
|
| 2009 |
Segal NH, Reidy-Lagunes D, Capanu M, Kemeny N, Chung K, Kelsen D, Hollywood E, Goodman-Davis N, Saltz LB. Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4087. PMID 27961665 DOI: 10.1200/Jco.2009.27.15_Suppl.4087 |
0.385 |
|
| 2009 |
Kemeny NE, Melendez FD, Capanu M, Paty PB, Fong Y, Schwartz LH, Jarnagin WR, Patel D, D'Angelica M. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3465-71. PMID 19470932 DOI: 10.1200/Jco.2008.20.1301 |
0.408 |
|
| 2009 |
Duffy A, Capanu M, Allen P, Kurtz R, Olson SH, Ludwig E, Klimstra DS, O'Reilly EM. Pancreatic adenocarcinoma in a young patient population - 12-Year experience at Memorial Sloan Kettering Cancer Center Journal of Surgical Oncology. 100: 8-12. PMID 19384918 DOI: 10.1002/Jso.21292 |
0.368 |
|
| 2009 |
Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, Fong Y. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer Annals of Oncology. 20: 1236-1241. PMID 19233901 DOI: 10.1093/Annonc/Mdn769 |
0.327 |
|
| 2009 |
Power DG, Schattner MA, Gerdes H, Brenner B, Markowitz AJ, Capanu M, Coit DG, Brennan M, Kelsen DP, Shah MA. Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer. Journal of the American College of Surgeons. 208: 173-8. PMID 19228527 DOI: 10.1016/J.Jamcollsurg.2008.10.022 |
0.366 |
|
| 2009 |
Gallagher DJ, Zheng J, Capanu M, Haviland D, Paty P, Dematteo RP, D'Angelica M, Fong Y, Jarnagin WR, Allen PJ, Kemeny N. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases Annals of Surgical Oncology. 16: 1844-1851. PMID 19224284 DOI: 10.1245/S10434-009-0348-1 |
0.393 |
|
| 2009 |
Knight JA, Bernstein L, Largent J, Capanu M, Begg CB, Mellemkjaer L, Lynch CF, Malone KE, Reiner AS, Liang X, Haile RW, Boice JD, Bernstein JL. Alcohol intake and cigarette smoking and risk of a contralateral breast cancer: The Women's Environmental Cancer and Radiation Epidemiology Study. American Journal of Epidemiology. 169: 962-8. PMID 19211621 DOI: 10.1093/Aje/Kwn422 |
0.324 |
|
| 2008 |
Kemeny NE, Capanu M, Fong Y, Haviland D, Jarnagin WR, DeMatteo RP, D'Angelica MI. Survival after resection of liver metastases from colorectal cancer with poor clinical risk factors using adjuvant systemic plus hepatic arterial therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4076. PMID 27949529 DOI: 10.1200/Jco.2008.26.15_Suppl.4076 |
0.381 |
|
| 2008 |
Huitzil FD, Sun MY, Capanu M, Blumgart LH, Jarnagin WR, Fong Y, DeMatteo RP, D'Angelica MI, Weiser MR, Abou-Alfa GK. Expression of the c-met and HGF in resected hepatocellular carcinoma (rHCC): Correlation with clinicopathological features (CP) and overall survival (OS). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4599. PMID 27948709 DOI: 10.1200/Jco.2008.26.15_Suppl.4599 |
0.311 |
|
| 2008 |
Duffy A, Capanu M, Allen P, Kurtz R, Ludwig E, Olson S, Klimstra D, Abou-Alfa GK, Kelsen DP, O'Reilly EM. Pancreatic adenocarcinoma (PAC) in a younger patient population: 10-year experience at Memorial Sloan-Kettering Cancer Center (MSKCC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4623. PMID 27948551 DOI: 10.1200/Jco.2008.26.15_Suppl.4623 |
0.306 |
|
| 2008 |
Duffy A, Capanu M, Abou‐Alfa GK, Huitzil D, Jarnagin W, Fong Y, D'Angelica M, DeMatteo RP, Blumgart LH, O'Reilly EM. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). Journal of Surgical Oncology. 98: 485-489. PMID 18802958 DOI: 10.1002/Jso.21141 |
0.385 |
|
| 2008 |
Concannon P, Haile RW, Børresen-Dale AL, Rosenstein BS, Gatti RA, Teraoka SN, Diep TA, Jansen L, Atencio DP, Langholz B, Capanu M, Liang X, Begg CB, Thomas DC, Bernstein L, et al. Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. Cancer Research. 68: 6486-91. PMID 18701470 DOI: 10.1158/0008-5472.Can-08-0134 |
0.334 |
|
| 2008 |
Ku GY, Ilson DH, Schwartz LH, Capanu M, O'Reilly E, Shah MA, Kelsen DP, Schwartz GK. Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer Cancer Chemotherapy and Pharmacology. 62: 875-880. PMID 18270704 DOI: 10.1007/S00280-008-0677-Y |
0.367 |
|
| 2008 |
Figueiredo JC, Bernstein L, Capanu M, Malone KE, Lynch CF, Anton-Culver H, Stovall M, Bertelsen L, Haile RW, Bernstein JL. Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: the WECARE Study Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1411-8. PMID 18250348 DOI: 10.1200/Jco.2007.14.3081 |
0.306 |
|
| 2008 |
Bertelsen L, Bernstein L, Olsen JH, Mellemkjaer L, Haile RW, Lynch CF, Malone KE, Anton-Culver H, Christensen J, Langholz B, Thomas DC, Begg CB, Capanu M, Ejlertsen B, Stovall M, et al. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. Journal of the National Cancer Institute. 100: 32-40. PMID 18159070 DOI: 10.1093/Jnci/Djm267 |
0.341 |
|
| 2008 |
Capanu M, Presnell B. Misspecification tests for binomial and beta-binomial models. Statistics in Medicine. 27: 2536-54. PMID 17914713 DOI: 10.1002/Sim.3049 |
0.657 |
|
| 2007 |
Lassmann S, Tang L, Capanu M, Brabletz T, Schöpflin A, Zur Hausen A, Gonen M, Kemeny N, Shia J, Klimstra D, Werner M. Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy. Gastroenterology. 133: 1831-9. PMID 18054556 DOI: 10.1053/J.Gastro.2007.08.075 |
0.379 |
|
| 2007 |
Gallagher DJ, Capanu M, Raggio G, Kemeny N. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: A retrospective analysis Annals of Oncology. 18: 1995-1999. PMID 17962209 DOI: 10.1093/Annonc/Mdm405 |
0.394 |
|
| 2007 |
Asmis TR, Capanu M, Kelsen DP, Shah MA. Systemic chemotherapy does not increase the risk of gastrointestinal perforation Annals of Oncology. 18: 2006-2008. PMID 17951596 DOI: 10.1093/Annonc/Mdm357 |
0.383 |
|
| 2007 |
Duffy A, Kortmansky J, Schwartz GK, Capanu M, Puleio S, Minsky B, Saltz L, Kelsen DP, O'Reilly EM. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma Annals of Oncology. 19: 86-91. PMID 17878176 DOI: 10.1093/Annonc/Mdm441 |
0.34 |
|
| 2007 |
Largent JA, Capanu M, Bernstein L, Langholz B, Mellemkaer L, Malone KE, Begg CB, Haile RW, Lynch CF, Anton-Culver H, Wolitzer A, Bernstein JL. Reproductive history and risk of second primary breast cancer: the WECARE study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 906-11. PMID 17507614 DOI: 10.1158/1055-9965.Epi-06-1003 |
0.311 |
|
| 2007 |
Duffy A, Capanu M, Abou-Alfa GK, Huitzel D, Williams P, Jarnagin W, Fong Y, Kelsen DP, O’Reilly EM. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC) Journal of Clinical Oncology. 25: 4648-4648. DOI: 10.1200/Jco.2007.25.18_Suppl.4648 |
0.402 |
|
| 2007 |
Huitzil FD, Capanu M, Jacobs G, Smith W, O'Reilly E, Shah M, Schwartz GK, Saltz LB, Kelsen DP, Abou-Alfa GK. Prognostic factors (PF) in advanced hepatocellular carcinoma (AHCC): Multivariate analysis and comparison between staging systems (SS) in patients (pts) treated at Memorial Sloan-Kettering Cancer Center (MSKCC) Journal of Clinical Oncology. 25: 4601-4601. DOI: 10.1200/Jco.2007.25.18_Suppl.4601 |
0.374 |
|
| 2007 |
Zhang W, Yang D, Capanu M, Hollywood E, Lue-Yat M, Borucka E, Azuma M, Gordon M, Saltz L, Lenz H. Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer Journal of Clinical Oncology. 25: 4128-4128. DOI: 10.1200/Jco.2007.25.18_Suppl.4128 |
0.337 |
|
| 2007 |
Kemeny NE, Capanu M, Huitzil-Melendez F, Haviland D, Fong Y, Jarnagin W, Blumgart L, DeMatteo R, D'Angelica M. Is neoadjuvant (neoadj) treatment necessary prior to liver resection in patients with resectable liver metastases (mets) from colorectal carcinoma (CRC) treated with post-resection hepatic arterial infusion (HAI) plus systemic (SYS) chemotherapy Journal of Clinical Oncology. 25: 14503-14503. DOI: 10.1200/Jco.2007.25.18_Suppl.14503 |
0.377 |
|
| 2006 |
Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 5201-6. PMID 17114652 DOI: 10.1200/Jco.2006.08.0887 |
0.351 |
|
| 2006 |
Abou-Alfa GK, Carvajal RD, Chung KY, Ghossein RA, Capanu M, Gonen M, Jacobs G, Kelsen DP, Schwartz GK. A non-randomized phase II study of sequential irinotecan (CPT) and flavopiridol (F) in patients (pts) with advanced hepatocellular carcinoma (HCC) Journal of Clinical Oncology. 24: 4148-4148. DOI: 10.1200/Jco.2006.24.18_Suppl.4148 |
0.302 |
|
| 2006 |
Ilson DH, Bains M, Rizk N, Shah M, Rusch V, Capanu M, Flores R, Kelsen D, Park B, Kepler S, Minsky B. Phase II trial of preoperative cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy: PET scan after induction therapy may identify early treatment failure Journal of Clinical Oncology. 24: 4023-4023. DOI: 10.1200/Jco.2006.24.18_Suppl.4023 |
0.344 |
|
| 2006 |
Shah MA, Ramanathan RK, Ilson D, Randazzo J, Schwartz GK, Tse A, D’Adamo D, Levner A, Capanu M, Kelsen DP. Final results of a multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI #6447) Journal of Clinical Oncology. 24: 4020-4020. DOI: 10.1200/Jco.2006.24.18_Suppl.4020 |
0.367 |
|
| Show low-probability matches. |